# RETRACTION: α‐Synuclein Conformational Antibodies Fused to Penetratin are Effective in Models of Lewy Body Disease

## TL;DR

This paper was retracted due to duplicated figures, which undermines the validity of its claims about treating Lewy Body Disease.

## Contribution

The paper originally claimed novel therapeutic potential of α-synuclein antibodies fused to penetratin in Lewy Body Disease models.

## Key findings

- The paper reported that α-synuclein conformational antibodies fused to penetratin were effective in disease models.
- It suggested these antibodies could reduce α-synuclein pathology and improve behavioral outcomes.
- The findings were based on data presented in figures later found to contain duplications.

## Abstract

RETRACTION:
SpencerB.
,
WilliamsS.
,
RockensteinE.
,
ValeraE.
,
XinW.
,
ManteM.
,
FlorioJ.
,
AdameA.
,
MasliahE.
, and
SierksM.R.
, “α‐Synuclein Conformational Antibodies Fused to Penetratin are Effective in Models of Lewy Body Disease,” Annals of Clinical and Translational Neurology
3, no. 8 (2016): 588–606, 10.1002/acn3.321.27606342
PMC4999592

The above article, published online on 16 June 2016, in Wiley Online Library (http://onlinelibrary.wiley.com/), has been retracted by agreement between the journal Editor‐in‐Chief, Ahmet Hoke; the American Neurological Association; and Wiley Periodicals LLC. Following publication, a third party contacted the publisher with concerns about duplications in Figures 1A, 3A, 3C, and 4A. Additionally, duplicated panels were discovered for Figure 5 with an earlier publication by some of the same authors (Fields et al., 2016 [https://doi.org/10.1186/s12974‐016‐0585‐8]). The retraction has been agreed to because of evidence that significant portions of multiple figures were duplicated, affecting the interpretation of the data and results presented. Author Eliezer Masliah did not indicate his agreement with the retraction. The other authors did not respond to communications from the Publisher regarding the retraction.